Lifeforce Capital — 2022 Investments
6 investments dated 2022 · listed companies and verified rows first · show all
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersOrbiMedDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+10 more
64x provides a platform and product suite for manufacturing advanced therapeutics, including gene therapies, cell therapies, and biologics.
BiotechDeep TechMedical Devices
Co-investorsBoxGroupFirst Round CapitalFifty YearsFuture VenturesNorthpond VenturesRefactor Capital+1 more
64x Bio develops cell-line engineering and production technologies to overcome manufacturing bottlenecks in advanced and next-generation therapies.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Lexi Rovner(CEO, Co-founder, Board of Directors)inAlexis Rovner(Founder)Ryan GallagherEmily Hawkins(Head of Talent)George Church, PhD(Co-founder, Scientific Advisory Board)David Thompson, PhD(Co-founder, Scientific Advisory Board)
Co-investorsFifty YearsFuture VenturesG VenturesRaptor GroupY CombinatorAlix Ventures+8 more
MindRight Health provides culturally affirming mental health support through a community-based platform and network of peer supporters.
Digital HealthHealthtechMental HealthSaaSWellness & FitnessMiami, US
Ashley Edwards(Founder)inAlexander Phillip Zito(Executive Officer)Jacob Slome Rauchbach(Executive Officer, Director)
Co-investorsAcumen AmericaDigitalDx VenturesGaingelsImpact America Fund
Liver transplant and drug testing
Co-investorsSelvedge Ventureah! VenturesKhosla VenturesNorrsken VC
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.
AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB
Quin Wills(Founder/CSO)inJack O'Meara(Founder)in
BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle
Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaGaingels+18 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

















__Twitter.png)










